BPMC 89.33 (+3.26%)
US09627Y1091BiotechnologyBiotechnology

Blueprint Medicines (BPMC) Stock Highlights

89.33 | +3.26%
2024-09-19 00:47:19
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. Its other drug candidate is BLU 554 FOR Advanced Hepatocellular Carcinoma, and BLU-667 for Ret Mutations, Fusions, and Predicted Resistant Mutants.

Statistics

Range Today
86.23 91.13
Volume Today 532.98K
Range 1 Year
43.89 121.9
Volume 1 Year 183.35M
Range 3 Year
37.82 121.9
Volume 3 Year 504.95M
Range 10 Year
13.04 125.61
Volume 10 Year 1.18B

Highlights

Market Capitalization 5.63B (mid)
Floating Shares 62.64M
Current Price 89.33
Price To Earnings -24.95
Price To Revenue 14.62
Price To Book 17.53
Earnings Per Share -3.41
Payout Ratio 0%

Performance

Latest +3.26%
1 Month -4.31%
3 Months -13.98%
6 Months -1.68%
1 Year +77.24%
3 Years -14.26%
5 Years +10.49%
10 Years +281.75%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.